These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2338629)

  • 1. Pharmacokinetics of two alternative dosage forms for cyclosporine: liposomes and intralipid.
    Venkataram S; Awni WM; Jordan K; Rahman YE
    J Pharm Sci; 1990 Mar; 79(3):216-9. PubMed ID: 2338629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine.
    Gruber SA; Venkataram S; Canafax DM; Cipolle RJ; Bowers L; Elsberry D; McGuiggan M; Hynes PE; Ritz JA; Gould FH
    Pharm Res; 1989 Jul; 6(7):601-7. PubMed ID: 2798309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and organ distribution of cyclosporin A incorporated in liposomes and mixed micelles.
    Lee MK; Choi L; Kim MH; Kim CK
    Int J Pharm; 1999 Nov; 191(2):87-93. PubMed ID: 10564835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of co-administration of Intralipid on the pharmacokinetics of cyclosporine in the rabbit.
    Shah AK; Sawchuk RJ
    Biopharm Drug Dispos; 1991; 12(6):457-66. PubMed ID: 1932609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of cyclosporine G in patients with renal failure.
    Wenk M; Bindschedler M; Costa E; Zuber M; Vozeh S; Thiel G; Abisch E; Keller HP; Beveridge T; Follath F
    Transplantation; 1988 Mar; 45(3):558-61. PubMed ID: 3347936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporine-phenytoin interaction.
    D'Souza MJ; Pollock SH; Solomon HM
    Drug Metab Dispos; 1988; 16(2):256-8. PubMed ID: 2898343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of incorporating cyclosporine into liposomes to reduce its nephrotoxicity.
    Smeesters C; Giroux L; Vinet B; Arnoux R; Chaland P; Corman J; St-Louis G; Daloze P
    Can J Surg; 1988 Jan; 31(1):34-6. PubMed ID: 3257403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity.
    Guada M; Sebastián V; Irusta S; Feijoó E; Dios-Viéitez Mdel C; Blanco-Prieto MJ
    Int J Nanomedicine; 2015; 10():6541-53. PubMed ID: 26527872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine-cimetidine interaction.
    D'Souza MJ; Pollock SH; Solomon HM
    Drug Metab Dispos; 1988; 16(1):57-9. PubMed ID: 2894956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid.
    Lo YL; Liu FI; Yang JM; Cherng JY
    Anticancer Res; 2001; 21(1A):445-50. PubMed ID: 11299776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and chronic toxicity of cyclosporine A in genetic hydroxylation-deficient dark Agouti rats.
    Koehn S; Frey FJ; Speck RF; Zeugin T; Schaffner T; Zimmermann A; Frey BM
    J Pharmacokinet Biopharm; 1990 Oct; 18(5):381-99. PubMed ID: 2266495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunosuppressive effect of cyclosporin A incapsulated into liposomes].
    Arnoux R; Dufourcq J; Smeesters C; Lalanne J; Deminière C; Penin E; Clerc M; Poteaux L; Dartigues JF; Michel A
    Chirurgie; 1990; 116(8-9):699-703. PubMed ID: 2129987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and biotransformation of the cyclosporine metabolite M-17 in the rabbit.
    Copeland K; Lukowski M; Yatscoff R; Thliveris J; Honcharik N
    Drug Metab Dispos; 1990; 18(2):226-30. PubMed ID: 1971578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The preparation and evaluation of a tablet dosage form of cyclosporine in dogs.
    Abdallah HY; Mayersohn M
    Pharm Res; 1991 Apr; 8(4):518-22. PubMed ID: 1871050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of cyclosporine. I. Single dose and constant rate infusion studies in the rabbit.
    Awni WM; Sawchuk RJ
    Drug Metab Dispos; 1985; 13(2):127-32. PubMed ID: 2859157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation.
    Guada M; Lana H; Gil AG; Dios-Viéitez Mdel C; Blanco-Prieto MJ
    Eur J Pharm Biopharm; 2016 Apr; 101():112-8. PubMed ID: 26877154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal tubular transport of cyclosporine A (CSA) and associated changes in renal function.
    Caterson RJ; Duggin GG; Critchley L; Baxter C; Horvath JS; Hall BM; Tiller DJ
    Clin Nephrol; 1986; 25 Suppl 1():S30-3. PubMed ID: 3519028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetically determined cyclosporine dosage in young children.
    Hoppu K; Koskimies O; Holmberg C; Hirvisalo EL
    Pediatr Nephrol; 1991 Jan; 5(1):1-4. PubMed ID: 2025515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution.
    Aliabadi HM; Brocks DR; Lavasanifar A
    Biomaterials; 2005 Dec; 26(35):7251-9. PubMed ID: 16005061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic analysis of cyclosporine in adjuvant arthritic rats.
    Pollock SH; Matthews HW; D'Souza MJ
    Drug Metab Dispos; 1989; 17(6):595-9. PubMed ID: 2575493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.